Information about Cariprazine
Cariprazine is an atypical antipsychotic used in the treatment of schizophrenia and manic or mixed episodes of bipolar disorder.
Liver safety of Cariprazine
Cariprazine has been associated with a low rate of serum aminotransferase elevations during therapy, but it has not been linked to instances of clinically apparent acute liver injury.
Mechanism of action of Cariprazine
Cariprazine (kar ip' ra zeen) is an atypical antipsychotic which appears to act as a partial agonist of dopamine type 2 (D2) and 3 (D3) receptors. The D2 and D3 receptors have been identified as targets for therapy of schizophrenia where they appear to be overstimulated. Cariprazine also may have some degree of activity against selected serotonin receptors (5-HT1A). In short term clinical trials, cariprazine was shown to improve symptoms in patients with schizophrenia and manic or mixed episodes of bipolar I disorder.
FDA approval information for Cariprazine
Cariprazine was approved for these indications in the United States in 2015 and is available in capsules of 1.5, 3, 4.5 and 6 mg under the brand name Vraylar.
Dosage and administration for Cariprazine
The recommended initial dose is 1.5 mg once daily, with subsequent dose increases based upon efficacy and tolerance to 3 to 6 mg daily.
Side effects of Cariprazine
Common side effects include dizziness, sedation, somnolence, nausea, weight gain, restlessness, tremor, akathisia and extrapyramidal symptoms. More serious adverse events can include cerebrovascular events such as transient ischemic attacks, particularly in the elderly with dementia, neurologic malignant syndrome, marked weight gain, dyslipidemia, diabetes, and orthostatic hypotension.
Second Generation (Atypicals)
- Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Iloperidone, Lurasidone, Olanzapine, Paliperidone, Pimavanserin, Quetiapine, Risperidone, Ziprasidone